RENATUS HAS BEEN GRANTED A KEY PATENT FOR NOVEL CYCLODEXTRINS
Renatus has been granted a key patent for novel cyclodextrins for the treatment of cholesterol-driven diseases by Korea Intellectual Property Office (KIPO).
Renatus, a pharma company pioneering next generation cyclodextrin-based therapies for the safe treatment of cholesterol-associated diseases, today opened its official website to public.